<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02851745</url>
  </required_header>
  <id_info>
    <org_study_id>G113</org_study_id>
    <nct_id>NCT02851745</nct_id>
  </id_info>
  <brief_title>Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry</brief_title>
  <acronym>DYDA2</acronym>
  <official_title>Effects of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart Care Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione dell'Associazione Medici Diabetologi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heart Care Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the effect of linagliptin 5 mg daily versus&#xD;
      the corresponding placebo on the LV systolic function (measured by midwall shortening&#xD;
      analysis) in patients with T2DM and a documented baseline concentric LV geometry and LV&#xD;
      systolic dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentre, randomized, double blind, parallel group comparison of an DPP-4 inhibitor,&#xD;
      linagliptin 5 mg od, versus placebo (1:1) in patients with T2DM and a documented baseline&#xD;
      concentric LV geometry and LV systolic dysfunction.&#xD;
&#xD;
      The management of glycemia will be left to the Investigator's judgment informed by clinical&#xD;
      guidelines. The Investigator will therefore be allowed to undertake appropriate action, i.e.:&#xD;
&#xD;
        -  Adjust the background antidiabetic treatment.&#xD;
&#xD;
        -  Prescribe an additional antidiabetic medication according to its labeling (with the&#xD;
           exclusion of other DPP-4 inhibitor or GLP-1 receptor agonist).&#xD;
&#xD;
      The enrollment period will last 12 months. The patients will be followed up for 48 weeks from&#xD;
      randomization.&#xD;
&#xD;
      After the randomization the patients will have a control visit after 2 weeks (Visit 3) and at&#xD;
      3 months from randomization (Visit 4, week 12). At Visit 4 blood samples will be collected.&#xD;
&#xD;
      Afterwards the patients will have one control visit at 24 weeks from randomization (Visit 5)&#xD;
      and a final visit at 48 weeks from randomization (Visit 6) with echocardiogram and ECG&#xD;
      performed and blood samples collected.&#xD;
&#xD;
      Patients still on study treatment at the time of final visit (Visit 6) will have a post&#xD;
      treatment safety follow up (clinical visit or phone contact) 30 days after the study&#xD;
      treatment discontinuation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 2, 2019</completion_date>
  <primary_completion_date type="Actual">July 2, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in LV systolic function</measure>
    <time_frame>48 weeks</time_frame>
    <description>Statistically significant change (equivalent to an increase of 10%) from baseline to 48 weeks of LV systolic function measured by analysis of the MFS (centralized reading).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in diastolic LV function</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes from baseline to 48 weeks of diastolic LV function (centralized reading) classified, in the two moments of evaluation, in 4 stages: normal, mild dysfunction, moderate and severe dysfunction. The efficacy of treatment will be evaluated both in terms of significant reduction of the parameter E / E 'expressed as a continuous variable and as entity improvement of dysfunction analyzed by degrees, as described above.&#xD;
Changes from baseline to 48 weeks of longitudinal LV systolic function (centralized reading) measured by tissue Doppler (peak systolic velocity of the wave S 'mitral ring); percentage of patients showing an improvement of S '&gt; 25% from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Left Ventricular Systolic Dysfunction</condition>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin 5 mg daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 5 mg daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <arm_group_label>Linagliptin</arm_group_label>
    <other_name>Trajenta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged equal to or more than 40 years at screening.&#xD;
&#xD;
          -  Patients with history of T2DM lasting at least six month prior to the screening visit.&#xD;
&#xD;
          -  HbA1c ≤ 8.0% (≤ 64 mmol/mol) at screening.&#xD;
&#xD;
          -  Evidence of sinus rhythm at screening ECG evaluation&#xD;
&#xD;
          -  No clinical signs/symptoms of a cardiac disease and no evidence of coronary artery&#xD;
             disease on the basis of clinical, electrocardiographic and echocardiographic&#xD;
             evaluation at screening.&#xD;
&#xD;
          -  Evidence at baseline echocardiographic examination of concentric left ventricular&#xD;
             geometry, defined as relative wall thickness ≥ 0.42. Relative wall thickness was&#xD;
             calculated as the end-diastolic ratio 2* posterior wall thickness/LV diameter.&#xD;
&#xD;
          -  Evidence at baseline echocardiographic examination of LV systolic dysfunction defined&#xD;
             as Midwall shortening (MFS) ≤15%&#xD;
&#xD;
          -  Obtained informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a confirmed indication for an incretin treatment&#xD;
&#xD;
          -  Uncontrolled diabetes: HbA1c &gt;8.0% (&gt; 64 mmol/mol) or Fasting Plasma Glucose &gt; 300&#xD;
             mg/dL measured at screening visit.&#xD;
&#xD;
          -  Glitazones within the last three months&#xD;
&#xD;
          -  Permanent atrial fibrillation&#xD;
&#xD;
          -  Uncontrolled hypertension (defined as systolic blood pressure&gt;160 and/or diastolic&#xD;
             blood pressure &gt;90)&#xD;
&#xD;
          -  Unstable dosage and changes in type of antihypertensive, lipid lowering and&#xD;
             antidiabetic drugs within 4 weeks before the screening visit.&#xD;
&#xD;
          -  Severe chronic renal dysfunction (defined as estimated glomerular filtration rate &lt; 30&#xD;
             ml/min/1.73 m2).&#xD;
&#xD;
          -  Previous or current documented history of untreated (by using CPAP) obstructive sleep&#xD;
             apnea syndrome&#xD;
&#xD;
          -  Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis.&#xD;
&#xD;
          -  Previous or current documented history of malignant disease&#xD;
&#xD;
          -  Pregnancy and breast feeding&#xD;
&#xD;
          -  Documented alcohol and drug abuse&#xD;
&#xD;
          -  Anticipated poor compliance&#xD;
&#xD;
          -  Current participation in a clinical trial with other investigational products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo B. Giorda, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale Maggiore - Diabetologia Malattie Metaboliche - Chieri</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni Xxiii</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. Garibaldi-Nesima</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo Della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>FG</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Villa Scassi</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iclas-Istituto Clinico Ligure Alta Spec.</name>
      <address>
        <city>Rapallo</city>
        <state>GE</state>
        <zip>16035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuseppe Da Copertino</name>
      <address>
        <city>Copertino</city>
        <state>LE</state>
        <zip>73043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico G. Martino</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Policlinico Multimedica</name>
      <address>
        <city>Sesto San Giovanni</city>
        <state>MI</state>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>Piemonte</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sandro Pertini</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore</name>
      <address>
        <city>Chieri</city>
        <state>TO</state>
        <zip>10023</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mauriziano</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aas 1 Triestina</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <zip>34148</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aorn Osp. Dei Colli- Po Vincenzo Monaldi</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda Universita' Di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura Villa Bianca</name>
      <address>
        <city>Trento</city>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Giorda CB, Cioffi G, Lucci D, Nada E, Ognibeni F, Mancusi C, Latini R, Maggioni AP; DYDA 2 Investigators. Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population. Cardiovasc Drugs Ther. 2019 Oct;33(5):547-555. doi: 10.1007/s10557-019-06898-6.</citation>
    <PMID>31418140</PMID>
  </reference>
  <results_reference>
    <citation>Cioffi G, Giorda CB, Lucci D, Nada E, Ognibeni F, Mancusi C, Latini R, Maggioni AP; DYDA 2 investigators. Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial. Eur J Prev Cardiol. 2021 Mar 23;28(1):8-17. doi: 10.1177/2047487320939217. Epub 2020 Jul 28.</citation>
    <PMID>33755143</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

